:strip_icc()/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2020/I/4/B5L38fRKCLtYIaUWH6Cw/2020-04-01t051213z-112374322-rc2hvf9c7s82-rtrmadp-3-health-coronavirus-usa.jpg)
[ad_1]
The data was collected at 16 treatment centers for the disease between February 11-29, 2020 in China. This is, according to the authors, the first randomized study on the drug: with the random choice of the participants. It was not double blind: when researchers and respondents do not know if they received treatment, a strategy to avoid psychological influence or personal and external impression.
The scientists waited 28 days for the test results to be negative for the virus. A total of 109 patients (73%), 56 without the drug and 53 with the drug, had this disease converted before the deadline. Another 41 (27%) were withdrawn from the study because they still had Sars CoV-2 at the end of 4 weeks.
The result: both groups had a similar result in response to treatment. The probability that the hydroxychloroquine group was cured during the study analysis period was 85.4%. Those who did not receive the drug had a probability of 81.3%, a difference of 4.1%. The margin of error was 10.3% to 18.5%.
Side effects were recorded in 7 of 80 patients who did not receive hydroxychloroquine (9%). Among those who received the drug, 21 people experienced adverse events among a total of 71 hydroxychloroquine receptors (30%). Diarrhea was the most common effect among participants taking the drug: 10% of them, 7 out of 70. Two had serious adverse effects from the drug.
